WHAT DO IBD PATIENTS FIND IMPORTANT IN THEIR TREATMENT?
“What do you find important in your (IBD?) treatment?”, “Which quality of life effects are important to you?”, “Which side-effects do you want to avoid?”, “Which characteristics should future drugs have according to you?”
To address these questions, EFCCA has embarked on exciting research with the University of Leuven (KU Leuven – Belgium). Via a survey, this study aims to find out which aspects, factors, and characteristics are important for patients when choosing a treatment for inflammatory bowel disease.
The survey has been translated into several languages and can be completed by clicking here!!!
ABOUT THE PROJECT
There is very little scientific evidence on patient preference targeted at the IBD patient community. This is why EFCCA decided to embark on this project which started in 2020 with an in-depth literature review and a cooperation agreement with KU Leuven university (Belgium). KU Leuven had already run a country level survey on IBD patient preferences which, together with other similar studies on other disease areas, has become the starting point of our multi-annual project.
KU LEUVEN country level study (Belgium) on IBD patient preferences
WHAT CAN WE LEARN FROM PATIENTS?
Patient preference studies can inform us about:
-
What matters to the patients
-
How much does it matter?
-
What matters most?
-
What trade-offs are patients prepared to make?
-
What are the risks that patients are prepared to take?
-
-
Information about preference heterogeneity
-
Treatment and disease experience
-
Time since diagnosis
-
MAIN OBJECTIVES
-
To reveal the unmet needs IBD patients have with respect to treatments for IBD
-
To quantify the importance (“weight”) of relevant IBD treatment attributes
-
Evaluate the Monoclonal Antibody Resistance that IBD patients express for different treatment alternatives
-
To determine preference heterogeneity, i.e., to investigate how preferences are influenced by participants’ characteristics
Download Presentations:
Presentation_quantitative_study.pdf
CONTEXT AND PARTNERS
-
European study (countries outside Europe can also participate)
-
IBD patients – minimum 18 years old
-
As inclusive as possible
-
Recruitment: physicians and patient organisations across Europe
PROJECT TEAM
KU LEUVEN researchers and EFCCA representatives
WHAT ARE WE DOING AT THE MOMENT?
KU Leuven researchers and EFCCA representatives brainstormed and worked on shared understanding and definition of attributes and structure of the study. Then the pilot phase started (September 2022). It consisted in interviewing English native speaker patients to get a honest and direct feedback on attributes and survey. The pilot phase remained open until the end of 2022.
In 2023 we targeted the countries and translated the survey into 14 languages.
Now we are running a social media campaign for awareness raising and recruitment with EFCCA members and clinicians involved. Our ultimate goal is to achieve a general picture on the patient preferences at European level and analysing country data for comparison.
Publication of Qualitative Study (This has been published in the Journal of Chron's and Colitis)
Elise Schoefs, PhD Researcher–KU Leuven also presented our joint survey on IBD patient preferences at the ISPOR Europe conference, ECCO Congress and DIA Europe in 2023.
Poster_ISPOR_attribute_development_final.pdf